Source: https://www.cnn.com/2021/01/17/asia/...hnk/index.html
Confidence in Chinese vaccines has taken a hit. But as coronavirus cases grow, some countries are still pushing ahead
By Helen Regan, CNN
Updated 11:55 PM ET, Sun January 17, 2021
Hong Kong (CNN)Mass public vaccination programs using a Chinese coronavirus vaccine are underway across Indonesia and Turkey, where tens of millions of people are expected to receive doses of the CoronaVac shot made by Beijing-based company Sinovac.
On Wednesday, Indonesian President Joko Widodo was shown receiving the country's first CoronaVac shot, after the government authorized it for emergency use. While on Thursday, Turkish President Recep Tayyip Erdogan announced he had also received the vaccine.
But the rollouts come despite a growing number of questions over the effectiveness of the shot, which last week was revealed to have an efficacy rate of just 50.38% in late-stage trials in Brazil -- significantly lower than earlier results showed. That rate only barely crosses the 50% efficacy threshold as set by the World Health Organization, and far lower than the 78% previously announced to much fanfare in China earlier this month.
The apparent discrepancy has led to concern among some scientists, and shaken international confidence in Chinese-made vaccines.
"Since many countries are planning to order, or have already ordered Sinovac's vaccines, it might undermine people's willingness to take them, because people may question the usefulness of the vaccines," said Yanzhong Huang, a senior fellow for global health at the US based Council on Foreign Relations and expert on the Chinese health care system. "It could be a potential stumbling block."
The Brazilian results suggest CoronaVac is far less effective than vaccines developed by Pfizer-BioNTech and Moderna, which have an efficacy rate of about 95%. Russia says its Sputnik V vaccine has an efficacy of 91%, while the UK's vaccine, developed by Oxford University and AstraZeneca, has an average efficacy of 70%. The Sinovac vaccine has a lower efficacy rate than its domestic Chinese competitor, developed by the state-owned Sinopharm, which it says has a 79.34% efficacy...
Confidence in Chinese vaccines has taken a hit. But as coronavirus cases grow, some countries are still pushing ahead
By Helen Regan, CNN
Updated 11:55 PM ET, Sun January 17, 2021
Hong Kong (CNN)Mass public vaccination programs using a Chinese coronavirus vaccine are underway across Indonesia and Turkey, where tens of millions of people are expected to receive doses of the CoronaVac shot made by Beijing-based company Sinovac.
On Wednesday, Indonesian President Joko Widodo was shown receiving the country's first CoronaVac shot, after the government authorized it for emergency use. While on Thursday, Turkish President Recep Tayyip Erdogan announced he had also received the vaccine.
But the rollouts come despite a growing number of questions over the effectiveness of the shot, which last week was revealed to have an efficacy rate of just 50.38% in late-stage trials in Brazil -- significantly lower than earlier results showed. That rate only barely crosses the 50% efficacy threshold as set by the World Health Organization, and far lower than the 78% previously announced to much fanfare in China earlier this month.
The apparent discrepancy has led to concern among some scientists, and shaken international confidence in Chinese-made vaccines.
"Since many countries are planning to order, or have already ordered Sinovac's vaccines, it might undermine people's willingness to take them, because people may question the usefulness of the vaccines," said Yanzhong Huang, a senior fellow for global health at the US based Council on Foreign Relations and expert on the Chinese health care system. "It could be a potential stumbling block."
The Brazilian results suggest CoronaVac is far less effective than vaccines developed by Pfizer-BioNTech and Moderna, which have an efficacy rate of about 95%. Russia says its Sputnik V vaccine has an efficacy of 91%, while the UK's vaccine, developed by Oxford University and AstraZeneca, has an average efficacy of 70%. The Sinovac vaccine has a lower efficacy rate than its domestic Chinese competitor, developed by the state-owned Sinopharm, which it says has a 79.34% efficacy...
Comment